Amifampridine is a potassium-channel blocker that prolongs nerve-terminal depolarisation to enhance acetylcholine release, used to improve neuromuscular transmission in Lambert-Eaton myasthenic syndrome. Simson Pharma's Amifampridine reference standard and impurities support compendial testing for this rare-disease therapy.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Amifampridine Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.
